Burleson & Co’s Idexx Laboratories IDXX Stock Holding History

Burleson & Co’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3	Closed	-$2K	–	470
2022 Q1	$2K	Buy	+3	New	+$1.58K	﹤0.01%	330

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Burleson & Co's IDXX Position: Q2 2022 in Review

Burleson & Co sold out of Idexx Laboratories (IDXX) in Q2 2022, closing a stake of 3 shares — an estimated $2K sold.

Burleson & Co first reported a position in IDXX in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 956 funds tracked by Wall St. Rank hold IDXX as of Q2 2022.

Burleson & Co reported no remaining Idexx Laboratories position as of Q2 2022 after selling out during the quarter.
Burleson & Co sold 3 Idexx Laboratories shares in Q2 2022, an estimated $2K.
Burleson & Co first reported a position in Idexx Laboratories in Q1 2022 and held it in 1 quarter.
Burleson & Co's Idexx Laboratories position peaked at $2K in Q1 2022.
956 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2022.

Based on Burleson & Co's 13F filing for Q2 2022, filed 13 Jul 2022.